| P50 | author | Akira Honda | Q51923732 |
| P2093 | author name string | Tadashi Ikegami | |
| P2860 | cites work | Intestinal permeability in cirrhotic patients with and without spontaneous bacterial peritonitis: is the ring closed? | Q43257958 |
| | Reduced diversity and imbalance of fecal microbiota in patients with ulcerative colitis | Q44544446 |
| | A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis | Q45040478 |
| | Quantitative estimations of the contribution of different bile acid pathways to total bile acid synthesis in the rat. | Q45108263 |
| | Faecal microbiota profiles as diagnostic biomarkers in primary sclerosing cholangitis | Q45225432 |
| | Comprehensive evaluation of the bactericidal activities of free bile acids in the large intestine of humans and rodents | Q46384502 |
| | Bile acid levels are increased in the liver of patients with steatohepatitis | Q46604037 |
| | Impact of commensal microbiota on the host pathophysiology: focusing on immunity and inflammation | Q46801201 |
| | The Bile Acid Chenodeoxycholic Acid Increases Human Brown Adipose Tissue Activity. | Q50999029 |
| | Intestinal microbiota in patients with nonalcoholic fatty liver disease. | Q54317263 |
| | Molecular pathogenesis of cholestasis. | Q54344101 |
| | Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives. | Q54372805 |
| | Characterization of fecal microbial communities in patients with liver cirrhosis. | Q54372904 |
| | Faecal microbiota profile of Crohn's disease determined by terminal restriction fragment length polymorphism analysis. | Q54510669 |
| | The gut-adherent microbiota of PSC-IBD is distinct to that of IBD. | Q54593558 |
| | Bile acids: natural ligands for an orphan nuclear receptor | Q22010063 |
| | Vitamin D receptor as an intestinal bile acid sensor | Q24297643 |
| | A G protein-coupled receptor responsive to bile acids | Q24338558 |
| | Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk | Q24603491 |
| | The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity | Q24630723 |
| | A core gut microbiome in obese and lean twins | Q24649648 |
| | A review of the medical treatment of primary sclerosing cholangitis in the 21st century | Q26771816 |
| | Bile acid-induced arrhythmia is mediated by muscarinic M2 receptors in neonatal rat cardiomyocytes | Q27332942 |
| | Endogenous bile acids are ligands for the nuclear receptor FXR/BAR | Q28198990 |
| | Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial | Q28253122 |
| | A metagenomic insight into our gut's microbiome | Q28265135 |
| | Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation | Q28290455 |
| | Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity | Q28512778 |
| | A metagenome-wide association study of gut microbiota in type 2 diabetes | Q29547726 |
| | Functional interactions between the gut microbiota and host metabolism | Q29616815 |
| | Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders | Q29617111 |
| | Biology of incretins: GLP-1 and GIP | Q29617302 |
| | Bifidobacteria can protect from enteropathogenic infection through production of acetate | Q29617592 |
| | Bile salt biotransformations by human intestinal bacteria | Q29622858 |
| | Bariatric surgery and nonalcoholic fatty liver disease. | Q30374196 |
| | Assignment of Eubacterium sp. VPI 12708 and related strains with high bile acid 7alpha-dehydroxylating activity to Clostridium scindens and proposal of Clostridium hylemonae sp. nov., isolated from human faeces | Q30597110 |
| | Clostridium hiranonis sp. nov., a human intestinal bacterium with bile acid 7alpha-dehydroxylating activity | Q30633160 |
| | Bile salt hydrolase of Bifidobacterium longum-biochemical and genetic characterization | Q30873903 |
| | The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects | Q33290848 |
| | Regulation of host weight gain and lipid metabolism by bacterial bile acid modification in the gut | Q33665593 |
| | Non-cell-autonomous activation of IL-6/STAT3 signaling mediates FGF19-driven hepatocarcinogenesis | Q33716459 |
| | Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c | Q33785270 |
| | Bile acid is a host factor that regulates the composition of the cecal microbiota in rats. | Q33992194 |
| | 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. | Q34143282 |
| | Plasma metabolomic profile in nonalcoholic fatty liver disease. | Q34180137 |
| | Symptomatic atherosclerosis is associated with an altered gut metagenome | Q34315625 |
| | Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation | Q36309525 |
| | Intestine-selective farnesoid X receptor inhibition improves obesity-related metabolic dysfunction | Q36379436 |
| | The bile acid membrane receptor TGR5 as an emerging target in metabolism and inflammation | Q36832832 |
| | Altered Bile Acid Metabolome in Patients with Nonalcoholic Steatohepatitis | Q36893921 |
| | Bile-acid-induced cell injury and protection | Q37157813 |
| | Neonatal gut microbiota associates with childhood multisensitized atopy and T cell differentiation. | Q37317826 |
| | Role of bile acids and bile acid receptors in metabolic regulation | Q37363616 |
| | Bile acid receptors in non-alcoholic fatty liver disease | Q37586952 |
| | Regulation of inflammation by short chain fatty acids | Q37976701 |
| | Perspective: TGR5 (Gpbar-1) in liver physiology and disease | Q38004227 |
| | Bile acid receptors as targets for drug development. | Q38132058 |
| | Nuclear bile acid signaling through the farnesoid X receptor | Q38289421 |
| | FXR agonists as therapeutic agents for non-alcoholic fatty liver disease | Q38359118 |
| | Bile Acid Signaling: Mechanism for Bariatric Surgery, Cure for NASH? | Q38516786 |
| | Mechanisms of enterohepatic fibroblast growth factor 15/19 signaling in health and disease. | Q38562150 |
| | Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies | Q38705659 |
| | Primary Biliary Cirrhosis Beyond Ursodeoxycholic Acid | Q38730924 |
| | Nuclear Receptor Modulation for the Treatment of Nonalcoholic Fatty Liver Disease. | Q38730938 |
| | Gut Microbiome-Based Metagenomic Signature for Non-invasive Detection of Advanced Fibrosis in Human Nonalcoholic Fatty Liver Disease | Q38806840 |
| | Finding the cure for primary biliary cholangitis - Still waiting | Q38858980 |
| | The roles of bile acids and sphingosine-1-phosphate signaling in the hepatobiliary diseases. | Q38909010 |
| | Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy | Q38954490 |
| | The ascending pathophysiology of cholestatic liver disease. | Q39040911 |
| | Hydrophobic bile acids suppress expression of AE2 in biliary epithelial cells and induce bile duct inflammation in primary biliary cholangitis | Q39424813 |
| | Bile acids and intestinal microbiota in autoimmune cholestatic liver diseases | Q39429267 |
| | Ursodeoxycholic acid amides as novel glucocorticoid receptor modulators. | Q39620127 |
| | Alterations and correlations of the gut microbiome, metabolism and immunity in patients with primary biliary cirrhosis | Q39723374 |
| | TGR5-mediated bile acid sensing controls glucose homeostasis | Q39805262 |
| | The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls | Q40787355 |
| | Obeticholic acid reduces bacterial translocation and inhibits intestinal inflammation in cirrhotic rats | Q40848070 |
| | New developments in the treatment of primary biliary cholangitis - role of obeticholic acid | Q41531249 |
| | Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome | Q42257409 |
| | Exendin 4 controls insulin production in rat islet beta cells predominantly by potentiation of glucose-stimulated proinsulin biosynthesis at the translational level | Q42503036 |
| | Fasting plasma chenodeoxycholic acid and cholic acid concentrations are inversely correlated with insulin sensitivity in adults | Q42841701 |
| | Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist | Q34326973 |
| | The phylogeny of the genus Clostridium: proposal of five new genera and eleven new species combinations. | Q34326978 |
| | Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease | Q34347996 |
| | Is bile acid a determinant of the gut microbiota on a high-fat diet? | Q34348990 |
| | Bile acids and the gut microbiome | Q34432618 |
| | Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. | Q34496310 |
| | Modulation of the fecal bile acid profile by gut microbiota in cirrhosis | Q34554908 |
| | Cirrhosis, bile acids and gut microbiota: unraveling a complex relationship. | Q34817375 |
| | Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice | Q34957338 |
| | Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity | Q35063271 |
| | Altered profile of human gut microbiome is associated with cirrhosis and its complications | Q35077209 |
| | Lowering bile acid pool size with a synthetic farnesoid X receptor (FXR) agonist induces obesity and diabetes through reduced energy expenditure | Q35128295 |
| | Alterations of the human gut microbiome in liver cirrhosis | Q35216354 |
| | Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. | Q35242565 |
| | The gut microbiota and inflammatory bowel disease | Q35446516 |
| | Findings From a Randomized Controlled Trial of Fecal Transplantation for Patients With Ulcerative Colitis | Q35594237 |
| | Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity | Q35672242 |
| | Implications of microbiota and bile acid in liver injury and regeneration | Q35740865 |
| | Dysbiosis in the Gut Microbiota of Patients with Multiple Sclerosis, with a Striking Depletion of Species Belonging to Clostridia XIVa and IV Clusters | Q35773313 |
| | The Gut Microbiota and Nonalcoholic Fatty Liver Disease | Q35778251 |
| | Characterization of Intestinal Microbiota in Ulcerative Colitis Patients with and without Primary Sclerosing Cholangitis | Q35829727 |
| | Intestinal Dysbiosis and Lowered Serum Lipopolysaccharide-Binding Protein in Parkinson's Disease | Q35833353 |
| | The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota | Q35850620 |
| | Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease | Q35893923 |
| | The features of mucosa-associated microbiota in primary sclerosing cholangitis | Q35917819 |
| | New Therapeutic Strategies for Primary Sclerosing Cholangitis. | Q35921865 |
| | Nonalcoholic Fatty Liver Disease and the Gut Microbiome | Q35985176 |
| | Bile Acids and Dysbiosis in Non-Alcoholic Fatty Liver Disease | Q36023779 |
| | Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD | Q36025017 |
| | Bacterial bile salt hydrolase in host metabolism: Potential for influencing gastrointestinal microbe-host crosstalk | Q36191869 |
| | The Human Intestinal Microbiome in Health and Disease | Q36224014 |
| | Metabolic effects of intestinal absorption and enterohepatic cycling of bile acids | Q36237911 |
| | Disease-Associated Changes in Bile Acid Profiles and Links to Altered Gut Microbiota. | Q36294238 |
| P433 | issue | 1 | |
| P304 | page(s) | 15-27 | |
| P577 | publication date | 2018-01-01 | |
| P1433 | published in | Hepatology Research | Q15752035 |
| P1476 | title | Reciprocal interactions between bile acids and gut microbiota in human liver diseases | |
| P478 | volume | 48 | |